Wegovy belongs to a class of medications called glucagon-like peptide-1 (GLP-1) receptor agonists , which were originally developed for type 2 diabetes management but have demonstrated significant efficacy in promoting weight loss
This triggers the secretion of growth hormone in a pulsatile, physiologic manner
We see the effect on diabetes, obesity, metabolic-associated steatotic liver disease, possibly with Alzheimer's, chronic obstructive pulmonary disease, and so many things
Not all compounding pharmacies maintain equal standards
This page does not provide medical advice, dosage guidance, treatment claims, patient-use instructions, or direct-to-consumer sales support.